首页 > 最新文献

Korean journal of clinical oncology最新文献

英文 中文
The current status of cancer survivorship care and a consideration of appropriate care model in Korea. 韩国癌症生存期护理现状及适宜护理模式的思考。
Pub Date : 2020-12-01 DOI: 10.14216/kjco.20017
Hye Mi Ko, Je-Ryong Kim, Jin Sun Lee

Purpose: Breast cancer patients with a human epidermal growth factor receptor 2 (HER2) enriched subtype are known to have higher rates of brain metastases (BM) than other patients. This study aimed to evaluate treatment options and survival outcomes.

Methods: A total of 115 breast cancer brain metastases (BCBM) patients with nearly complete medical records were retrospectively analyzed. Additionally, 36 patients were HER2 enriched types according to histological subtypes. The BM was found by brain magnetic resonance imaging in patients who had neurologic symptoms or by regular screening. Age, breast tumor size, number of BM, histological subtypes, first treatment of breast cancer, estrogen receptor, and HER2 status, stage, local treatment of BM were analyzed. Median overall survival, 5-year survival were analyzed from the data.

Results: The median survival time after BM was 6 months, the mean survival time was 16.3 months, and the 5-year survival after BM was only 8.0%. Factors that significantly affect the survival of BCBM patients include histological subtype, number of BM, use of lapatinib in multivariate analysis. A total of 19 out of 36 HER2 enriched patients were treated with lapatinib or capecitabine. For the treatment of HER2 enriched patients, additional use of blood-brain barrier (BBB) crossing substances, as well as local treatment for BM, significantly improve the survival rate in the Kaplan-Meier method (P=0.001).

Conclusion: A combination of local treatment modality for BCBM and the use of substances that cross the BBB for the HER2 enriched patient improved the survival rate.

目的:已知人表皮生长因子受体2 (HER2)富集亚型乳腺癌患者的脑转移(BM)率高于其他患者。本研究旨在评估治疗方案和生存结果。方法:回顾性分析115例几乎完整病历的乳腺癌脑转移(BCBM)患者。此外,根据组织学亚型,36例患者为HER2富集型。脑脊髓炎是在有神经系统症状的患者中通过脑磁共振成像或定期筛查发现的。分析年龄、乳腺肿瘤大小、BM数量、组织学亚型、乳腺癌首次治疗、雌激素受体、HER2状态、分期、BM局部治疗情况。根据数据分析中位总生存期、5年生存期。结果:脑转移后中位生存时间为6个月,平均生存时间为16.3个月,5年生存率仅为8.0%。在多因素分析中,影响BCBM患者生存的因素包括组织学亚型、BM数量、拉帕替尼的使用。36例HER2富集患者中有19例接受拉帕替尼或卡培他滨治疗。对于HER2富集患者的治疗,在Kaplan-Meier方法中,额外使用血脑屏障(BBB)穿越物质以及局部治疗BM可显著提高生存率(P=0.001)。结论:对于HER2富集的患者,局部治疗方式和使用穿过血脑屏障的物质相结合可提高生存率。
{"title":"The current status of cancer survivorship care and a consideration of appropriate care model in Korea.","authors":"Hye Mi Ko,&nbsp;Je-Ryong Kim,&nbsp;Jin Sun Lee","doi":"10.14216/kjco.20017","DOIUrl":"https://doi.org/10.14216/kjco.20017","url":null,"abstract":"<p><strong>Purpose: </strong>Breast cancer patients with a human epidermal growth factor receptor 2 (HER2) enriched subtype are known to have higher rates of brain metastases (BM) than other patients. This study aimed to evaluate treatment options and survival outcomes.</p><p><strong>Methods: </strong>A total of 115 breast cancer brain metastases (BCBM) patients with nearly complete medical records were retrospectively analyzed. Additionally, 36 patients were HER2 enriched types according to histological subtypes. The BM was found by brain magnetic resonance imaging in patients who had neurologic symptoms or by regular screening. Age, breast tumor size, number of BM, histological subtypes, first treatment of breast cancer, estrogen receptor, and HER2 status, stage, local treatment of BM were analyzed. Median overall survival, 5-year survival were analyzed from the data.</p><p><strong>Results: </strong>The median survival time after BM was 6 months, the mean survival time was 16.3 months, and the 5-year survival after BM was only 8.0%. Factors that significantly affect the survival of BCBM patients include histological subtype, number of BM, use of lapatinib in multivariate analysis. A total of 19 out of 36 HER2 enriched patients were treated with lapatinib or capecitabine. For the treatment of HER2 enriched patients, additional use of blood-brain barrier (BBB) crossing substances, as well as local treatment for BM, significantly improve the survival rate in the Kaplan-Meier method (P=0.001).</p><p><strong>Conclusion: </strong>A combination of local treatment modality for BCBM and the use of substances that cross the BBB for the HER2 enriched patient improved the survival rate.</p>","PeriodicalId":74045,"journal":{"name":"Korean journal of clinical oncology","volume":"16 2","pages":"110-118"},"PeriodicalIF":0.0,"publicationDate":"2020-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/90/40/kjco-16-2-110.PMC9942731.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9161595","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 13
Radiologic intervention due to delayed gastric emptying after pylorus preserving gastrectomy for gastric cancer does not affect pyloric function. 胃癌保幽门胃切除术后胃排空延迟的影像学干预不影响幽门功能。
Pub Date : 2020-12-01 DOI: 10.14216/kjco.20014
Hyun Tae Lim, Shin-Hoo Park, Jong-Ho Choi, Jae Seok Bae, Seong-Ho Kong, Do Joong Park, Hyuk-Joon Lee, Se Hyung Kim, Han-Kwang Yang

Purpose: The purpose of this study is to evaluate whether radiologic intervention in the pylorus decreases its function for delayed gastric emptying (DGE) patients after pylorus preserving gastrectomy (PPG) for gastric cancers and to determine the optimal interventional algorithm.

Methods: PPG patients who underwent intervention for DGE from January 2013 to December 2017 and a control group using propensity score matching were identified. Pyloric function was compared by subjective symptoms, postoperative upper gastrointestinal series at 3 months (short-term function), and esophagogastroduodenoscopy findings at 12 months (long-term function). Serum albumin levels and body weight change, 6 months and 12 months postoperatively, were compared to evaluate nutritional status. Interventional success rate, mean hospital stay, and recurrence of DGE were analyzed to determine the optimal intervention plan.

Results: Fifty-one out of 677 patients (7.53%) received intervention. There was no difference in pyloric function and nutritional status between the intervention and control groups. The interventional success rate for first-time balloon dilatation was 41.7% (20/48). If a second intervention was required and balloon dilatation was done, the success rate was 45.5% (5/11). However, if stent insertion was done, the success rate was 100% (17/17). Subsequent stent insertion after balloon dilatation resulted in a shorter mean hospital stay. Intervention including stent insertion had a lower recurrence of DGE than balloon only intervention (1.96% vs. 5.88%, P=0.041).

Conclusion: Radiologic intervention did not decrease long-term pyloric function. For treating DGE, if at first balloon dilatation fails, retrievable stent insertion can be considered as a second choice.

目的:本研究的目的是评估胃癌保幽门胃切除术(PPG)后胃排空延迟(DGE)患者的幽门放射干预是否会降低其功能,并确定最佳干预算法。方法:选取2013年1月至2017年12月接受DGE干预的PPG患者和采用倾向评分匹配的对照组。幽门功能通过主观症状、术后3个月的上消化道系列(短期功能)和12个月的食管胃十二指肠镜检查结果(长期功能)进行比较。比较术后6个月和12个月的血清白蛋白水平和体重变化,以评估营养状况。分析干预成功率、平均住院时间和DGE复发率,确定最佳干预方案。结果:677例患者中51例(7.53%)接受了干预。干预组和对照组在幽门功能和营养状况上没有差异。首次球囊扩张的介入成功率为41.7%(20/48)。如果需要进行第二次干预并进行球囊扩张,成功率为45.5%(5/11)。然而,如果植入支架,成功率为100%(17/17)。球囊扩张后的支架植入缩短了平均住院时间。包括支架置入的干预比单纯球囊干预的DGE复发率低(1.96%比5.88%,P=0.041)。结论:放射治疗对长期幽门功能无明显影响。对于治疗DGE,如果第一次球囊扩张失败,可考虑可回收支架置入作为第二选择。
{"title":"Radiologic intervention due to delayed gastric emptying after pylorus preserving gastrectomy for gastric cancer does not affect pyloric function.","authors":"Hyun Tae Lim,&nbsp;Shin-Hoo Park,&nbsp;Jong-Ho Choi,&nbsp;Jae Seok Bae,&nbsp;Seong-Ho Kong,&nbsp;Do Joong Park,&nbsp;Hyuk-Joon Lee,&nbsp;Se Hyung Kim,&nbsp;Han-Kwang Yang","doi":"10.14216/kjco.20014","DOIUrl":"https://doi.org/10.14216/kjco.20014","url":null,"abstract":"<p><strong>Purpose: </strong>The purpose of this study is to evaluate whether radiologic intervention in the pylorus decreases its function for delayed gastric emptying (DGE) patients after pylorus preserving gastrectomy (PPG) for gastric cancers and to determine the optimal interventional algorithm.</p><p><strong>Methods: </strong>PPG patients who underwent intervention for DGE from January 2013 to December 2017 and a control group using propensity score matching were identified. Pyloric function was compared by subjective symptoms, postoperative upper gastrointestinal series at 3 months (short-term function), and esophagogastroduodenoscopy findings at 12 months (long-term function). Serum albumin levels and body weight change, 6 months and 12 months postoperatively, were compared to evaluate nutritional status. Interventional success rate, mean hospital stay, and recurrence of DGE were analyzed to determine the optimal intervention plan.</p><p><strong>Results: </strong>Fifty-one out of 677 patients (7.53%) received intervention. There was no difference in pyloric function and nutritional status between the intervention and control groups. The interventional success rate for first-time balloon dilatation was 41.7% (20/48). If a second intervention was required and balloon dilatation was done, the success rate was 45.5% (5/11). However, if stent insertion was done, the success rate was 100% (17/17). Subsequent stent insertion after balloon dilatation resulted in a shorter mean hospital stay. Intervention including stent insertion had a lower recurrence of DGE than balloon only intervention (1.96% vs. 5.88%, P=0.041).</p><p><strong>Conclusion: </strong>Radiologic intervention did not decrease long-term pyloric function. For treating DGE, if at first balloon dilatation fails, retrievable stent insertion can be considered as a second choice.</p>","PeriodicalId":74045,"journal":{"name":"Korean journal of clinical oncology","volume":"16 2","pages":"89-95"},"PeriodicalIF":0.0,"publicationDate":"2020-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/f7/89/kjco-16-2-89.PMC9942724.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9161597","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Perianal extragastrointestinal stromal tumor. 肛周肠外间质瘤。
Pub Date : 2020-12-01 DOI: 10.14216/kjco.20021
Ayoung Kang, Sung Hwan Cho, Byung-Soo Park, Gyung Mo Son, Hyun Sung Kim, Jae-Joon Kim, Su Jin Kim, Dong Hoon Shin, Tae Un Kim

An extragastrointestinal stromal tumor (EGIST) is a gastrointestinal stromal tumor that arises outside of the gastrointestinal tract. Most EGISTs are located in the omentum, mesentery, and retroperitoneum. The occurrence of an EGIST at the perianal region is very rare. Herein, we report our experience with EGISTs in the perianal area and review the literature. A 70-year-old man presented to our hospital with a 2-year history of anal discomfort. A pelvic magnetic resonance imaging scan showed a homogenous, well-defined, soft tissue density mass. The patient underwent mass excision, and the pathological examination confirmed that the mass was an EGIST. The size of the tumor was 4.3×3.2 cm, and the mitotic count was 1 per 50 high-power fields. The tumor cells were immunohistochemically positive for KIT and CD34 but were negative for S-100 and alpha-smooth muscle actin. There were no other abnormal findings in the gastrointestinal tract; upon pathological review, this case was confirmed as perianal EGIST. Therefore, EGIST should be considered as a differential diagnosis of perianal masses.

胃肠外间质瘤(EGIST)是一种发生在胃肠道外的胃肠道间质瘤。大多数egist位于网膜、肠系膜和腹膜后。EGIST发生在肛周区域是非常罕见的。在此,我们报告肛周egist的治疗经验,并回顾相关文献。一名70岁男性以2年肛门不适病史来我院就诊。盆腔磁共振成像扫描显示均匀,界限分明,软组织密度肿块。患者行肿物切除,病理检查证实肿物为EGIST。肿瘤大小4.3×3.2 cm,高倍视野有丝分裂计数1 / 50。肿瘤细胞免疫组化KIT和CD34阳性,S-100和α -平滑肌肌动蛋白阴性。胃肠道未见其他异常;经病理检查,确诊为肛周EGIST。因此,EGIST应被视为鉴别诊断肛周肿块。
{"title":"Perianal extragastrointestinal stromal tumor.","authors":"Ayoung Kang,&nbsp;Sung Hwan Cho,&nbsp;Byung-Soo Park,&nbsp;Gyung Mo Son,&nbsp;Hyun Sung Kim,&nbsp;Jae-Joon Kim,&nbsp;Su Jin Kim,&nbsp;Dong Hoon Shin,&nbsp;Tae Un Kim","doi":"10.14216/kjco.20021","DOIUrl":"https://doi.org/10.14216/kjco.20021","url":null,"abstract":"<p><p>An extragastrointestinal stromal tumor (EGIST) is a gastrointestinal stromal tumor that arises outside of the gastrointestinal tract. Most EGISTs are located in the omentum, mesentery, and retroperitoneum. The occurrence of an EGIST at the perianal region is very rare. Herein, we report our experience with EGISTs in the perianal area and review the literature. A 70-year-old man presented to our hospital with a 2-year history of anal discomfort. A pelvic magnetic resonance imaging scan showed a homogenous, well-defined, soft tissue density mass. The patient underwent mass excision, and the pathological examination confirmed that the mass was an EGIST. The size of the tumor was 4.3×3.2 cm, and the mitotic count was 1 per 50 high-power fields. The tumor cells were immunohistochemically positive for KIT and CD34 but were negative for S-100 and alpha-smooth muscle actin. There were no other abnormal findings in the gastrointestinal tract; upon pathological review, this case was confirmed as perianal EGIST. Therefore, EGIST should be considered as a differential diagnosis of perianal masses.</p>","PeriodicalId":74045,"journal":{"name":"Korean journal of clinical oncology","volume":"16 2","pages":"138-141"},"PeriodicalIF":0.0,"publicationDate":"2020-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/24/27/kjco-16-2-138.PMC9942734.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9161599","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Risk factors of elderly patients with postoperative delirium following major abdominal surgery for cancer. 老年腹部肿瘤大手术后谵妄的危险因素分析。
Pub Date : 2020-12-01 DOI: 10.14216/kjco.20016
Seung Chul Heo, Hye Seong Ahn, Rumi Shin, Chang-Sup Lim, Dong-Seok Han

Purpose: Postoperative delirium (POD) is a common complication in elderly patients after major abdominal surgery for cancer. Although POD is related with a poor outcome, there have not been many reports about POD after abdominal surgery in Korea. The aims of study were to analyze the characteristics and surgical outcomes of elderly patients with POD and to identify the risk factors of POD.

Methods: From November 2016 to January 2019, we prospectively enrolled 63 patients who were aged ≥75 years and underwent major abdominal surgery for cancer. POD was daily assessed for up to 10 days postoperatively with the Confusion Assessment Method and a validated chart review.

Results: POD occurred in eight patients (12.7%). Univariate analysis showed that the occurrence of POD was related to sodium <135 mEq/L (P=0.037), combined resection (P=0.023), longer surgery/anesthesia time (P=0.023 and P=0.037, respectively), increased blood loss (P=0.004), postoperative admission to intensive care unit (ICU) (P=0.023), and duration of Foley catheter (P=0.011), however, multivariate analysis identified no significant risk factors of POD. There was no difference in postoperative outcomes such as hospital stay, mortality, reoperation, and morbidity between patients with POD and without POD.

Conclusion: Elderly patients with hyponatremia, combined resection, longer operation/anesthesia time and admission to ICU had tendencies to develop POD after major abdominal surgery. Surgeons should pay more attention to prevent POD, and a large-scale prospective study is needed to identify the risk factors of POD.

目的:术后谵妄(POD)是老年腹部肿瘤大手术后常见的并发症。虽然POD与预后不良有关,但在韩国,腹部手术后发生POD的报道并不多。本研究的目的是分析老年POD患者的特点和手术效果,并确定POD的危险因素。方法:2016年11月至2019年1月,前瞻性纳入63例年龄≥75岁且因癌症接受腹部大手术的患者。术后10天每天使用混淆评估法和有效的图表回顾评估POD。结果:发生POD 8例(12.7%)。结论:老年低钠血症、联合手术切除、手术/麻醉时间较长及入住ICU的患者在腹部大手术后有发生POD的倾向。外科医生应更加重视对POD的预防,需要大规模的前瞻性研究来确定POD的危险因素。
{"title":"Risk factors of elderly patients with postoperative delirium following major abdominal surgery for cancer.","authors":"Seung Chul Heo,&nbsp;Hye Seong Ahn,&nbsp;Rumi Shin,&nbsp;Chang-Sup Lim,&nbsp;Dong-Seok Han","doi":"10.14216/kjco.20016","DOIUrl":"https://doi.org/10.14216/kjco.20016","url":null,"abstract":"<p><strong>Purpose: </strong>Postoperative delirium (POD) is a common complication in elderly patients after major abdominal surgery for cancer. Although POD is related with a poor outcome, there have not been many reports about POD after abdominal surgery in Korea. The aims of study were to analyze the characteristics and surgical outcomes of elderly patients with POD and to identify the risk factors of POD.</p><p><strong>Methods: </strong>From November 2016 to January 2019, we prospectively enrolled 63 patients who were aged ≥75 years and underwent major abdominal surgery for cancer. POD was daily assessed for up to 10 days postoperatively with the Confusion Assessment Method and a validated chart review.</p><p><strong>Results: </strong>POD occurred in eight patients (12.7%). Univariate analysis showed that the occurrence of POD was related to sodium <135 mEq/L (P=0.037), combined resection (P=0.023), longer surgery/anesthesia time (P=0.023 and P=0.037, respectively), increased blood loss (P=0.004), postoperative admission to intensive care unit (ICU) (P=0.023), and duration of Foley catheter (P=0.011), however, multivariate analysis identified no significant risk factors of POD. There was no difference in postoperative outcomes such as hospital stay, mortality, reoperation, and morbidity between patients with POD and without POD.</p><p><strong>Conclusion: </strong>Elderly patients with hyponatremia, combined resection, longer operation/anesthesia time and admission to ICU had tendencies to develop POD after major abdominal surgery. Surgeons should pay more attention to prevent POD, and a large-scale prospective study is needed to identify the risk factors of POD.</p>","PeriodicalId":74045,"journal":{"name":"Korean journal of clinical oncology","volume":"16 2","pages":"104-109"},"PeriodicalIF":0.0,"publicationDate":"2020-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/1d/4a/kjco-16-2-104.PMC9942723.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9169785","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Clinical experience of immune checkpoint inhibitor for a metastatic jejunal cancer patient with a high tumor mutational burden and low expression of programmed death-ligand 1. 免疫检查点抑制剂治疗高肿瘤突变负荷、程序性死亡配体1低表达转移性空肠癌的临床经验
Pub Date : 2020-06-01 DOI: 10.14216/kjco.20010
Seo Ree Kim, Sang Hoon Chun, Ji Hyun Kim, Sang-Yeob Kim, Bo-In Lee, Chan Kwon Jung, Jin Hyoung Kang

Recent data showed that DNA mismatch repair deficiency can be a predictive biomarker for a favorable response of immune checkpoint inhibitors regardless of tumor type due to give rise to high tumor mutational burden (TMB) and microsatellite instability (MSI). Loss-of-function mutations of a specific tumor suppressor gene can also lead to good response to immunotherapy. Herein, we report a case exhibiting good response to pembrolizumab in a jejunal adenocarcinoma patient with low programmed death-ligand 1 (PD-L1) expression. A 67-year-old man underwent surgical resection followed by adjuvant chemotherapy. After 10 months, he was treated with palliative chemotherapy due to hepatic and pulmonary metastases. However, palliative chemotherapy did not have any effect whatsoever. Based on genetic testing results of high TMB and high MSI in the resected primary tumor, pembrolizumab treatment was performed. After the three cycles of treatment, all metastatic lesions shrank remarkably. Considering the mechanism of immune checkpoint inhibitors, this case establishes the importance of genetic markers as TMB and MSI rather than PD-L1 expression by the prediction of their anti-tumor activities..

最近的数据显示,DNA错配修复缺陷可以作为免疫检查点抑制剂有利反应的预测性生物标志物,无论肿瘤类型如何,因为它会引起高肿瘤突变负担(TMB)和微卫星不稳定性(MSI)。特定肿瘤抑制基因的功能缺失突变也可以导致对免疫治疗的良好反应。在此,我们报告了一例对派姆单抗有良好反应的空肠腺癌患者,其程序性死亡配体1 (PD-L1)表达较低。一位67岁的男性接受了手术切除和辅助化疗。10个月后,由于肝和肺转移,他接受了姑息性化疗。然而,姑息性化疗没有任何效果。根据切除的原发肿瘤中高TMB和高MSI的基因检测结果,进行派姆单抗治疗。三个治疗周期后,所有转移灶均明显缩小。考虑到免疫检查点抑制剂的机制,本病例通过预测其抗肿瘤活性,确立了TMB和MSI等遗传标记比PD-L1表达更重要。
{"title":"Clinical experience of immune checkpoint inhibitor for a metastatic jejunal cancer patient with a high tumor mutational burden and low expression of programmed death-ligand 1.","authors":"Seo Ree Kim,&nbsp;Sang Hoon Chun,&nbsp;Ji Hyun Kim,&nbsp;Sang-Yeob Kim,&nbsp;Bo-In Lee,&nbsp;Chan Kwon Jung,&nbsp;Jin Hyoung Kang","doi":"10.14216/kjco.20010","DOIUrl":"https://doi.org/10.14216/kjco.20010","url":null,"abstract":"<p><p>Recent data showed that DNA mismatch repair deficiency can be a predictive biomarker for a favorable response of immune checkpoint inhibitors regardless of tumor type due to give rise to high tumor mutational burden (TMB) and microsatellite instability (MSI). Loss-of-function mutations of a specific tumor suppressor gene can also lead to good response to immunotherapy. Herein, we report a case exhibiting good response to pembrolizumab in a jejunal adenocarcinoma patient with low programmed death-ligand 1 (PD-L1) expression. A 67-year-old man underwent surgical resection followed by adjuvant chemotherapy. After 10 months, he was treated with palliative chemotherapy due to hepatic and pulmonary metastases. However, palliative chemotherapy did not have any effect whatsoever. Based on genetic testing results of high TMB and high MSI in the resected primary tumor, pembrolizumab treatment was performed. After the three cycles of treatment, all metastatic lesions shrank remarkably. Considering the mechanism of immune checkpoint inhibitors, this case establishes the importance of genetic markers as TMB and MSI rather than PD-L1 expression by the prediction of their anti-tumor activities..</p>","PeriodicalId":74045,"journal":{"name":"Korean journal of clinical oncology","volume":"16 1","pages":"57-62"},"PeriodicalIF":0.0,"publicationDate":"2020-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/9e/51/kjco-16-1-57.PMC9942715.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9161585","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Clinical study of colorectal cancer operation: Survival analysis. 结直肠癌手术的临床研究:生存分析。
Pub Date : 2020-06-01 DOI: 10.14216/kjco.20002
Youngki Hong, Jaelim Kim, Yoon Jung Choi, Jung Gu Kang

Purpose: Overall 5-year survival rates for colon and rectal cancer reported recently by the American Cancer Society were 89%, 90% for localized disease, 71%, 71% for regional disease, and 14%, 15% for distant disease. But the results of survival rate of colorectal cancer in a single institution were very rare. The aim of this study is to evaluate surgical results and survival rates of colorectal cancer.

Methods: We conducted a retrospective study with patients who underwent curative resection for a primary colorectal adenocarcinoma between 2009 and 2018.

Results: Five-year overall and disease-free survival were 79.5% and 69.9%, respectively. The overall 5-year survival by stages was 94.7% in stage I, 88.4% in stage II, 74.3% in stage III and 31.5% in stage IV. Five-year disease-free survival was 91% in stage I, 79.8% in stage II, 63.3% in stage III, and 18.9% in stage IV. The overall 5-year survival in rectal cancer was superior to colon cancer (P=0.014) while there was no difference in 5-year disease-free survival (P=0.338). Overall survival in female patients was better than male patient (P=0.029). Overall survival by age was worst in group of less than 40 years old (62.5%), and best in group between 41 and 65 years old (86.5%). Postoperative mortality within 30 days was 0.4%, and the recurrence rate was 19.2%.

Conclusion: With the development of surgical skills and various treatments, postoperative outcome of colorectal cancer is expected to improve. It may be helpful for surgeons to improve their surgical outcomes when they review their data and conduct active researches.

目的:美国癌症协会最近报道的结肠癌和直肠癌的总体5年生存率为:局部疾病89%,90%,局部疾病71%,71%,远处疾病14%,15%。但结直肠癌在单一机构的存活率的结果非常罕见。本研究的目的是评估结直肠癌的手术效果和生存率。方法:我们对2009年至2018年间接受根治性切除的原发性结直肠癌患者进行了回顾性研究。结果:5年总生存率和无病生存率分别为79.5%和69.9%。分期总5年生存率I期为94.7%,II期为88.4%,III期为74.3%,IV期为31.5%。5年无病生存率I期为91%,II期为79.8%,III期为63.3%,IV期为18.9%。直肠癌总5年生存率优于结肠癌(P=0.014), 5年无病生存率无差异(P=0.338)。女性患者的总生存率优于男性患者(P=0.029)。总生存率以40岁以下组最差(62.5%),41 ~ 65岁组最佳(86.5%)。术后30 d内死亡率0.4%,复发率19.2%。结论:随着手术技术的发展和各种治疗方法的应用,结直肠癌术后预后有望得到改善。这可能有助于外科医生检讨他们的资料,并进行积极的研究,以提高他们的手术效果。
{"title":"Clinical study of colorectal cancer operation: Survival analysis.","authors":"Youngki Hong,&nbsp;Jaelim Kim,&nbsp;Yoon Jung Choi,&nbsp;Jung Gu Kang","doi":"10.14216/kjco.20002","DOIUrl":"https://doi.org/10.14216/kjco.20002","url":null,"abstract":"<p><strong>Purpose: </strong>Overall 5-year survival rates for colon and rectal cancer reported recently by the American Cancer Society were 89%, 90% for localized disease, 71%, 71% for regional disease, and 14%, 15% for distant disease. But the results of survival rate of colorectal cancer in a single institution were very rare. The aim of this study is to evaluate surgical results and survival rates of colorectal cancer.</p><p><strong>Methods: </strong>We conducted a retrospective study with patients who underwent curative resection for a primary colorectal adenocarcinoma between 2009 and 2018.</p><p><strong>Results: </strong>Five-year overall and disease-free survival were 79.5% and 69.9%, respectively. The overall 5-year survival by stages was 94.7% in stage I, 88.4% in stage II, 74.3% in stage III and 31.5% in stage IV. Five-year disease-free survival was 91% in stage I, 79.8% in stage II, 63.3% in stage III, and 18.9% in stage IV. The overall 5-year survival in rectal cancer was superior to colon cancer (P=0.014) while there was no difference in 5-year disease-free survival (P=0.338). Overall survival in female patients was better than male patient (P=0.029). Overall survival by age was worst in group of less than 40 years old (62.5%), and best in group between 41 and 65 years old (86.5%). Postoperative mortality within 30 days was 0.4%, and the recurrence rate was 19.2%.</p><p><strong>Conclusion: </strong>With the development of surgical skills and various treatments, postoperative outcome of colorectal cancer is expected to improve. It may be helpful for surgeons to improve their surgical outcomes when they review their data and conduct active researches.</p>","PeriodicalId":74045,"journal":{"name":"Korean journal of clinical oncology","volume":"16 1","pages":"3-8"},"PeriodicalIF":0.0,"publicationDate":"2020-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/0d/06/kjco-16-1-3.PMC9942716.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9215090","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 8
The importance of identifying risk factor for contralateral occult carcinoma. 确定对侧隐性癌风险因素的重要性。
Pub Date : 2020-06-01 Epub Date: 2020-06-30 DOI: 10.14216/kjco.20001
Joon-Hyop Lee
{"title":"The importance of identifying risk factor for contralateral occult carcinoma.","authors":"Joon-Hyop Lee","doi":"10.14216/kjco.20001","DOIUrl":"10.14216/kjco.20001","url":null,"abstract":"","PeriodicalId":74045,"journal":{"name":"Korean journal of clinical oncology","volume":"16 1","pages":"1-2"},"PeriodicalIF":0.0,"publicationDate":"2020-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/bb/8c/kjco-16-1-1.PMC9942718.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9161586","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
What predicts better prognosis in elderly breast cancer patients? 如何预测老年乳腺癌患者预后较好?
Pub Date : 2020-06-01 DOI: 10.14216/kjco.20009
Youn Joo Jung, Seungju Lee, Hyun Yul Kim, Hyun-June Paik, Chang Shin Jung, Jee Yeon Kim, Hyuk Jae Jung, Seokwon Lee, Choongrak Kim

Purpose: As we enter an aging society, the number of elderly patients with breast cancer is increasing. We assessed the prognostic factors for breast cancer recurrence or metastasis in patients over the age of 65 years by analyzing tumor characteristics and long-term clinical outcomes.

Methods: In this retrospective study, the data of 286 breast cancer patients aged 65 years and older, who underwent treatment at the Pusan National University Hospital and Pusan National University Yangsan Hospital from 2008 to 2014, were analyzed. The patients were divided into two groups: those with recurrence or metastasis and those without. Cox-regression model was used to analyze the risk factors for recurrence or metastasis. Kaplan-Meier method was used to analyze survival rates by the log-rank test.

Results: Among the 286 patients with invasive breast cancer, 43 patients (15.0%) had recurrence or distant metastasis during a median follow-up period of 61 months. Advanced stages of breast cancer and patients who are not adapted to endocrine therapy were associated with poor prognosis.

Conclusion: In this study, advanced stages of breast cancer and endocrine therapy were the prognostic factors for breast cancer recurrences or metastases. Early detection of elderly breast cancer generally increases the possibility of diagnosis at an earlier stage, which can lead to a better prognosis. Moreover, endocrine therapy should be administered to elderly patients who manifest favorable intrinsic subtypes of breast cancer.

目的:随着我们进入老龄化社会,老年乳腺癌患者数量不断增加。我们通过分析肿瘤特征和长期临床结果来评估65岁以上患者乳腺癌复发或转移的预后因素。方法:回顾性分析2008 - 2014年在釜山大学附属医院和釜山大学梁山医院就诊的286例65岁及以上乳腺癌患者的资料。患者分为两组:复发或转移组和无复发或转移组。采用cox -回归模型分析复发或转移的危险因素。生存率采用Kaplan-Meier法,log-rank检验。结果:286例浸润性乳腺癌患者中,有43例(15.0%)在61个月的中位随访期间发生复发或远处转移。晚期乳腺癌和不适应内分泌治疗的患者预后较差。结论:在本研究中,乳腺癌晚期及内分泌治疗是乳腺癌复发或转移的预后因素。老年乳腺癌的早期发现通常会增加早期诊断的可能性,从而导致更好的预后。此外,内分泌治疗应给予老年患者谁表现出有利的内在亚型乳腺癌。
{"title":"What predicts better prognosis in elderly breast cancer patients?","authors":"Youn Joo Jung,&nbsp;Seungju Lee,&nbsp;Hyun Yul Kim,&nbsp;Hyun-June Paik,&nbsp;Chang Shin Jung,&nbsp;Jee Yeon Kim,&nbsp;Hyuk Jae Jung,&nbsp;Seokwon Lee,&nbsp;Choongrak Kim","doi":"10.14216/kjco.20009","DOIUrl":"https://doi.org/10.14216/kjco.20009","url":null,"abstract":"<p><strong>Purpose: </strong>As we enter an aging society, the number of elderly patients with breast cancer is increasing. We assessed the prognostic factors for breast cancer recurrence or metastasis in patients over the age of 65 years by analyzing tumor characteristics and long-term clinical outcomes.</p><p><strong>Methods: </strong>In this retrospective study, the data of 286 breast cancer patients aged 65 years and older, who underwent treatment at the Pusan National University Hospital and Pusan National University Yangsan Hospital from 2008 to 2014, were analyzed. The patients were divided into two groups: those with recurrence or metastasis and those without. Cox-regression model was used to analyze the risk factors for recurrence or metastasis. Kaplan-Meier method was used to analyze survival rates by the log-rank test.</p><p><strong>Results: </strong>Among the 286 patients with invasive breast cancer, 43 patients (15.0%) had recurrence or distant metastasis during a median follow-up period of 61 months. Advanced stages of breast cancer and patients who are not adapted to endocrine therapy were associated with poor prognosis.</p><p><strong>Conclusion: </strong>In this study, advanced stages of breast cancer and endocrine therapy were the prognostic factors for breast cancer recurrences or metastases. Early detection of elderly breast cancer generally increases the possibility of diagnosis at an earlier stage, which can lead to a better prognosis. Moreover, endocrine therapy should be administered to elderly patients who manifest favorable intrinsic subtypes of breast cancer.</p>","PeriodicalId":74045,"journal":{"name":"Korean journal of clinical oncology","volume":"16 1","pages":"52-56"},"PeriodicalIF":0.0,"publicationDate":"2020-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/9d/3e/kjco-16-1-52.PMC9942720.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9161584","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Risk factor for contralateral occult carcinoma in patients with unilateral papillary thyroid carcinoma. 单侧乳头状甲状腺癌对侧隐匿癌的危险因素。
Pub Date : 2020-06-01 DOI: 10.14216/kjco.20006
Ha Rim Ahn, Sang Yull Kang, Hyun Jo Youn, Sung Hoo Jung

Purpose: The extent of surgery necessary in patients with unilateral papillary thyroid carcinoma (PTC) on preoperative radiologic imaging is still in doubt. In this study, we aimed to define risk factors that could be indicators for malignant nodules in the contralateral thyroid lobe.

Methods: We included 438 patients who underwent total thyroidectomy between January 2011 and December 2014 at our institution. In this study, patients were divided into two groups according to the presence of contralateral occult carcinoma identified by postoperative pathological examination. We analyzed the clinicopathologic factors including characteristics of coexistent nodules in the contralateral lobe based on preoperative radiological imaging.

Results: A total of 96 patients (21.9%) had PTC in the contralateral lobe. There were no significant differences between patients with or without contralateral occult carcinoma with respect to gender, age, primary tumor size, central lymph node metastasis, extrathyroidal extension and stage. The presence of Hashimoto's thyroiditis was an independent predictive factor for contralateral occult carcinoma (P=0.01).

Conclusion: A risk factor for contralateral occult carcinoma in unilateral PTC patients is Hashimoto's thyroiditis. Therefore, more caution is needed when determining optimal surgical methods for PTC patients with Hashimoto's thyroiditis.

目的:单侧甲状腺乳头状癌(PTC)患者术前影像学需要手术的程度尚不明确。在本研究中,我们旨在确定可能作为对侧甲状腺叶恶性结节指标的危险因素。方法:我们纳入了2011年1月至2014年12月在我院接受甲状腺全切除术的438例患者。本研究根据术后病理检查是否存在对侧隐匿性癌,将患者分为两组。我们分析了临床病理因素,包括术前影像学检查对侧肺叶共存结节的特征。结果:对侧肺叶PTC 96例(21.9%)。对侧隐匿性癌患者在性别、年龄、原发肿瘤大小、中央淋巴结转移、甲状腺外扩张及分期等方面无显著差异。桥本甲状腺炎是对侧隐匿性癌的独立预测因素(P=0.01)。结论:桥本甲状腺炎是单侧PTC患者发生对侧隐匿性癌的危险因素。因此,在确定PTC合并桥本甲状腺炎患者的最佳手术方法时,需要更加谨慎。
{"title":"Risk factor for contralateral occult carcinoma in patients with unilateral papillary thyroid carcinoma.","authors":"Ha Rim Ahn,&nbsp;Sang Yull Kang,&nbsp;Hyun Jo Youn,&nbsp;Sung Hoo Jung","doi":"10.14216/kjco.20006","DOIUrl":"https://doi.org/10.14216/kjco.20006","url":null,"abstract":"<p><strong>Purpose: </strong>The extent of surgery necessary in patients with unilateral papillary thyroid carcinoma (PTC) on preoperative radiologic imaging is still in doubt. In this study, we aimed to define risk factors that could be indicators for malignant nodules in the contralateral thyroid lobe.</p><p><strong>Methods: </strong>We included 438 patients who underwent total thyroidectomy between January 2011 and December 2014 at our institution. In this study, patients were divided into two groups according to the presence of contralateral occult carcinoma identified by postoperative pathological examination. We analyzed the clinicopathologic factors including characteristics of coexistent nodules in the contralateral lobe based on preoperative radiological imaging.</p><p><strong>Results: </strong>A total of 96 patients (21.9%) had PTC in the contralateral lobe. There were no significant differences between patients with or without contralateral occult carcinoma with respect to gender, age, primary tumor size, central lymph node metastasis, extrathyroidal extension and stage. The presence of Hashimoto's thyroiditis was an independent predictive factor for contralateral occult carcinoma (P=0.01).</p><p><strong>Conclusion: </strong>A risk factor for contralateral occult carcinoma in unilateral PTC patients is Hashimoto's thyroiditis. Therefore, more caution is needed when determining optimal surgical methods for PTC patients with Hashimoto's thyroiditis.</p>","PeriodicalId":74045,"journal":{"name":"Korean journal of clinical oncology","volume":"16 1","pages":"33-38"},"PeriodicalIF":0.0,"publicationDate":"2020-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/c7/1b/kjco-16-1-33.PMC9942722.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9161592","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 2
Comparison of clinical outcomes between sentinel lymph node biopsy and axillary lymph node dissection in a single-center Z0011-eligible breast cancer cohort. 在符合z0011标准的单中心乳腺癌队列中前哨淋巴结活检和腋窝淋巴结清扫的临床结果比较
Pub Date : 2020-06-01 DOI: 10.14216/kjco.20004
Heein Jo, Eun-Gyeong Lee, Eunjin Song, Jai Hong Han, So-Youn Jung, Han-Sung Kang, Eun Sook Lee, Seeyoun Lee

Purpose: The ACOSOG Z0011 trial has proven the oncological safety of sentinel lymph node biopsy (SLBx) for node negative breast cancer. Accordingly, treatment paradigm including axilla surgery was changed. We retrospectively reviewed breast cancer patients to evaluate the clinical effect of paradigm shift in breast cancer surgery after applying the Z0011 criteria.

Methods: All women who underwent breast-conserving surgery at the National Cancer Center between January 1, 2000, and December 31, 2015, were enrolled and classified according to the Z0011 criteria. The primary endpoint of the study was the disease-free survival rates, and the secondary was the adverse events, especially arm lymphedema.

Results: Total 361 patients were enrolled the study (271 axillary lymph node dissection [ALND] group, 90 SLBx group). After the Z0011 guideline was adopted in our institute, the use of ALND decreased, and lymph node sampling (removing only a few axillary lymph nodes) replaced ALND. The total mean number of retrieved nodes were more in ALND group (13.02) than SLBx group (3.43). However, there was no difference in the mean number of positive nodes between two groups (2.34 in ALND group vs. 1.12 in SLBx group, P=0.001). During follow-up, 25 patients experienced disease recurrence: 22 from the ALND group and three from the SLBx group. All of died seven patients were from the ALND group. The ALND group had more complications than the SLBx group (P=0.02). Arm edema occurred more frequently in the ALND group (29.5%) than in the SLBx group (5.6%), although without statistical significance (P=0.07).

Conclusion: In our study, we concluded that SLBx can be used safely in Z0011-eligible cohort without increased risk of locoregional recurrence. Moreover, we found that omission of ALND is favored to reduce some serious complications such as arm lymphedema.

目的:ACOSOG Z0011试验证明了前哨淋巴结活检(SLBx)治疗淋巴结阴性乳腺癌的肿瘤学安全性。因此,改变了包括腋窝手术在内的治疗模式。我们回顾性地回顾了乳腺癌患者,以评估应用Z0011标准后乳腺癌手术中范式转移的临床效果。方法:所有于2000年1月1日至2015年12月31日期间在国家癌症中心接受保乳手术的女性,按照Z0011标准进行分类。研究的主要终点是无病生存率,次要终点是不良事件,特别是手臂淋巴水肿。结果:共纳入361例患者,其中腋窝淋巴结清扫组271例,SLBx组90例。我院采用Z0011指南后,ALND的使用减少,淋巴结取样(仅切除少量腋窝淋巴结)取代了ALND。ALND组总平均检索节点数(13.02个)高于SLBx组(3.43个)。然而,两组间平均阳性淋巴结数无差异(ALND组为2.34个,SLBx组为1.12个,P=0.001)。随访期间,25例患者出现疾病复发:22例来自ALND组,3例来自SLBx组。死亡7例均为ALND组。ALND组并发症发生率高于SLBx组(P=0.02)。ALND组上肢水肿发生率(29.5%)高于SLBx组(5.6%),但差异无统计学意义(P=0.07)。结论:在我们的研究中,我们得出结论,SLBx可以安全地用于符合z0011条件的队列,而不会增加局部复发的风险。此外,我们发现,遗漏ALND有利于减少一些严重的并发症,如手臂淋巴水肿。
{"title":"Comparison of clinical outcomes between sentinel lymph node biopsy and axillary lymph node dissection in a single-center Z0011-eligible breast cancer cohort.","authors":"Heein Jo,&nbsp;Eun-Gyeong Lee,&nbsp;Eunjin Song,&nbsp;Jai Hong Han,&nbsp;So-Youn Jung,&nbsp;Han-Sung Kang,&nbsp;Eun Sook Lee,&nbsp;Seeyoun Lee","doi":"10.14216/kjco.20004","DOIUrl":"https://doi.org/10.14216/kjco.20004","url":null,"abstract":"<p><strong>Purpose: </strong>The ACOSOG Z0011 trial has proven the oncological safety of sentinel lymph node biopsy (SLBx) for node negative breast cancer. Accordingly, treatment paradigm including axilla surgery was changed. We retrospectively reviewed breast cancer patients to evaluate the clinical effect of paradigm shift in breast cancer surgery after applying the Z0011 criteria.</p><p><strong>Methods: </strong>All women who underwent breast-conserving surgery at the National Cancer Center between January 1, 2000, and December 31, 2015, were enrolled and classified according to the Z0011 criteria. The primary endpoint of the study was the disease-free survival rates, and the secondary was the adverse events, especially arm lymphedema.</p><p><strong>Results: </strong>Total 361 patients were enrolled the study (271 axillary lymph node dissection [ALND] group, 90 SLBx group). After the Z0011 guideline was adopted in our institute, the use of ALND decreased, and lymph node sampling (removing only a few axillary lymph nodes) replaced ALND. The total mean number of retrieved nodes were more in ALND group (13.02) than SLBx group (3.43). However, there was no difference in the mean number of positive nodes between two groups (2.34 in ALND group vs. 1.12 in SLBx group, P=0.001). During follow-up, 25 patients experienced disease recurrence: 22 from the ALND group and three from the SLBx group. All of died seven patients were from the ALND group. The ALND group had more complications than the SLBx group (P=0.02). Arm edema occurred more frequently in the ALND group (29.5%) than in the SLBx group (5.6%), although without statistical significance (P=0.07).</p><p><strong>Conclusion: </strong>In our study, we concluded that SLBx can be used safely in Z0011-eligible cohort without increased risk of locoregional recurrence. Moreover, we found that omission of ALND is favored to reduce some serious complications such as arm lymphedema.</p>","PeriodicalId":74045,"journal":{"name":"Korean journal of clinical oncology","volume":"16 1","pages":"18-24"},"PeriodicalIF":0.0,"publicationDate":"2020-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/5e/22/kjco-16-1-18.PMC9942717.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9169779","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Korean journal of clinical oncology
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1